How to select the best upfront therapy for metastatic disease? Focus on <i>ALK</i>-rearranged non-small cell lung cancer (NSCLC).

Transl Lung Cancer Res · 2020 · PMC7815371 · PMID 33489815

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significanceP=0.09so close (0.05 < p ≤ 0.1)

The ORR was higher in the alectinib group (82.9%; 95% CI, 76.0–88.5%) compared to crizotinib (75.5%; 95% CI, 67.8–82.1%) but did not reach statistical significance (P=0.09).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.